Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Chen

Showing results (441-450 of 491) with videos related to

Pageof 50
Sort By:
Arxiv|November 24, 2025
ITRUSST Consensus on Biophysical Safety for Transcranial Ultrasound StimulationJean-François Aubry, David Attali, Mark E Schafer, et al.
Brain Stimulation|October 10, 2025
ITRUSST consensus on biophysical safety for transcranial ultrasound stimulationJean-François Aubry, David Attali, Mark E Schafer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.
Blood Advances|November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysisAriela Noy, Sven de Vos, Morton Coleman, et al.
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Blood|July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaNancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
Vaccine|March 12, 2025
Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021Omotayo Bolu, Oluwafemi D Alo, Emem Iwara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL)Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|November 25, 2020
Canadian recommendations for training and performance in basic perioperative point-of-care ultrasound: recommendations from a consensus of Canadian anesthesiology academic centresMassimiliano Meineri, Ramiro Arellano, Gregory Bryson, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Pageof 50

Showing results (441-450 of 491) with videos related to

Sort By:
Pageof 50
Arxiv|November 24, 2025
ITRUSST Consensus on Biophysical Safety for Transcranial Ultrasound StimulationJean-François Aubry, David Attali, Mark E Schafer, et al.
Brain Stimulation|October 10, 2025
ITRUSST consensus on biophysical safety for transcranial ultrasound stimulationJean-François Aubry, David Attali, Mark E Schafer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.
Blood Advances|November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysisAriela Noy, Sven de Vos, Morton Coleman, et al.
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Blood|July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaNancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
Vaccine|March 12, 2025
Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021Omotayo Bolu, Oluwafemi D Alo, Emem Iwara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL)Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|November 25, 2020
Canadian recommendations for training and performance in basic perioperative point-of-care ultrasound: recommendations from a consensus of Canadian anesthesiology academic centresMassimiliano Meineri, Ramiro Arellano, Gregory Bryson, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Pageof 50